Ryan D. Schubert,Robert C. Axtell,Jeffrey Edward Dunn
申请号：
US14781885
公开号：
US20160054320A1
申请日:
2014.04.04
申请国别(地区):
US
年份:
2016
代理人:
摘要：
Compositions and methods are provided for classification of individuals suffering from a demyelinating disease into groups that are informative of the individuals responsiveness or lack of responsiveness to treatment with a J3-interferon (IFNJ3) acting therapy. In particular, it is shown that the effective immunomodulatory treatment of demyelinating disease with IFNJ3 is associated with an increase in circulating transitional B cells in the patient. Diseases of interest include without limitation inflammatory demyelinating diseases of the central nervous system, e.g. multiple sclerosis, neuromyelitis optica (NMO), experimental autoimmune encephalitis (EAE), acute disseminated encephalomyelitis (ADEM), etc.
